Wish to keep on prime of the science and politics driving biotech at the moment? Join to get our biotech e-newsletter in your inbox.
Good morning. A reminder that should you’re ever feeling down a couple of mistake you made, there may be at all times a solution to flip it round — like how this supply robotic firm has turned the difficulty of its robotic crashing into my native bus cease right into a advertising and marketing alternative.
The necessity-to-know this morning
Revolution Medicines raised $2 billion in concurrent inventory and debt choices. The mammoth financings — double what the corporate supposed to lift — come simply days after daraxonrasib, its experimental therapy for superior pancreatic most cancers, was proven to double the median general survival of sufferers in a Section 3 scientific trial.
Bain Capital once more creates a startup with older pharma medication
After Bain Capital final summer time stated it licensed 5 immunology medication from Bristol Myers Squibb, it’s now unveiling the corporate to take these therapies ahead: a startup known as Beeline Medicines.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
